登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《JAMA，3月27日，Convalescent Plasma to Treat COVID-19 Possibilities and Challenges》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-03-28

  • Convalescent Plasma to Treat COVID-19

    Possibilities and Challenges

    John D. Roback, MD, PhD1; Jeannette Guarner, MD2

    Author Affiliations Article Information

    JAMA. Published online March 27, 2020. doi:10.1001/jama.2020.4940

    In this issue of JAMA, Shen et al report findings from a preliminary study of 5 severely ill patients with coronavirus disease 2019 (COVID-19) who were treated in the Shenzhen Third People's Hospital, China, using plasma from recovered individuals.1 All patients had severe respiratory failure and were receiving mechanical ventilation; 1 needed extracorporeal membrane oxygenation (ECMO) and 2 had bacterial and/or fungal pneumonia. Four patients without coexisting diseases received convalescent plasma around hospital day 20, and a patient with hypertension and mitral valve insufficiency received the plasma transfusion at day 10. The donor plasma had demonstrable IgG and IgM anti–SARS-CoV-19 antibodies and neutralized the virus in in vitro cultures.

  • 原文来源：https://jamanetwork.com/journals/jama/fullarticle/2763982?resultClick=1
115浏览量
原文链接
相关报告

  • 《JAMA，6月3日，Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-06-05
    • Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19 A Randomized Clinical Trial Ling Li, MD, PhD1,2; Wei Zhang, MD3,4; Yu Hu, MD, PhD5; et alXunliang Tong, MD, PhD6; Shangen Zheng, MD7; Juntao Yang, PhD8; Yujie Kong, MD1,2; Lili Ren, PhD9,10; Qing Wei, MD11; Heng Mei, MD, PhD5; Caiying Hu, MD12; Cuihua Tao, MD13,14; Ru Yang, MD15; Jue Wang, MD1,2; Yongpei Yu, PhD16; Yong Guo, PhD17; Xiaoxiong Wu, MD18; Zhihua Xu, MD12,19; Li Zeng, MD3,20; Nian Xiong, MD12,21; Lifeng Chen, MD22; Juan Wang, MD11; Ning Man, MD23; Yu Liu, PhD1; Haixia Xu, MD1,2; E. Deng, MS1; Xuejun Zhang, MS1; Chenyue Li, MD1,2; Conghui Wang, PhD9; Shisheng Su, PhD17; Linqi Zhang, PhD24; Jianwei Wang, PhD9,10; Yanyun Wu, MD, PhD25; Zhong Liu, MD, PhD1,2 Author Affiliations JAMA. Published online June 3, 2020. doi:10.1001/jama.2020.10044 Abstract Importance  Convalescent plasma is a potential therapeutic option for patients with coronavirus disease 2019 (COVID-19), but further data from randomized clinical trials are needed. Objective  To evaluate the efficacy and adverse effects of convalescent plasma therapy for patients with COVID-19. Design, Setting, and Participants  Open-label, multicenter, randomized clinical trial performed in 7 medical centers in Wuhan, China, from February 14, 2020, to April 1, 2020, with final follow-up April 28, 2020. The trial included 103 participants with laboratory-confirmed COVID-19 that was severe (respiratory distress and/or hypoxemia) or life-threatening (shock, organ failure, or requiring mechanical ventilation). The trial was terminated early after 103 of a planned 200 patients were enrolled.
    63浏览量
    原文链接

  • 《TAJP，5月27日，Treatment of COVID-19 Patients with Convalescent Plasma》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-05-28
    • Treatment of COVID-19 Patients with Convalescent Plasma Author links open overlay panelEricSalazarabKatherine K.PerezacMadihaAshrafdJianChenaBrianCastilloaPaul A.ChristensenaTarynEubankcDavid W.BernardabTodd N.EagarabS. WesleyLongabeSishirSubediaRandall J.OlsenabeChristopherLevequeaMary R.SchwartzaMonishaDeyaCherylChavez-EastaJohnRogersaAhmedShehabeldina…James M.Musserabe Show more https://doi.org/10.1016/j.ajpath.2020.05.014 Abstract COVID-19 disease, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread globally, and no proven treatments are available. Convalescent plasma therapy has been used with varying degrees of success to treat severe microbial infections for more than 100 years. Patients (n = 25) with severe and/or life-threatening COVID-19 disease were enrolled at the Houston Methodist hospitals from March 28 – April 14, 2020. Patients were transfused with convalescent plasma obtained from donors with confirmed SARS-CoV-2 infection and had recovered. The primary study outcome was safety, and the secondary outcome was clinical status at day 14 post-transfusion. Clinical improvement was assessed based on a modified World Health Organization 6-point ordinal scale and laboratory parameters. Viral genome sequencing was performed on donor and recipient strains.
    55浏览量
    原文链接